Evidence map›Paper›PMID 40610052›Full record

Trial reportThe European respiratory journal2025

Development and validation of a predictive 6-min walk score in patients with idiopathic pulmonary fibrosis.

Steven D Nathan, Jie Gao, Ho Cheol Kim, Abhimanyu Chandel, Henry Chen, Xiaomin Lu, Bernt van den Blink, Lixin Shao, Timothy R Watkins, Toby M Maher and 1 more

Abstract readValidation StudyRandomized Controlled Trial
In one paragraph

Trial report in The European respiratory journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Steven D NathanAdvanced Lung Disease and Transplant Program, Inova Fairfax Hospital, Falls Church, VA, USA steven.nathan@inova.org.ORCID https://orcid.org/0000-0002-6270-1617
Jie GaoGilead Sciences, Foster City, CA, USA.
Ho Cheol KimDepartment of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
Abhimanyu ChandelUniformed Services University of the Health Sciences, Bethesda, MD, USA.
Henry ChenGilead Sciences, Foster City, CA, USA.
Xiaomin LuGilead Sciences, Foster City, CA, USA.
Bernt van den BlinkGalapagos BV, Leiden, The Netherlands.
Lixin ShaoGilead Sciences, Foster City, CA, USA.
Timothy R WatkinsGilead Sciences, Foster City, CA, USA.
Toby M MaherDepartment of Pulmonary, Critical Care, and Sleep Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.ORCID https://orcid.org/0000-0001-7192-9149
Lisa LancasterDivision of Pulmonary, Allergy, and Critical Care Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe 6-min walk test (6MWT) provides an assessment of patient function and has been employed in interstitial lung disease clinical trials as an end-point. The ISABELA studies were two replicate randomised controlled trials of idiopathic pulmonary fibrosis (IPF) that included a regimented 6MWT protocol. The goal of this study was to combine 6MWT components into a pragmatic, easy to apply, composite clinical prediction score.

methods6MWT parameters associated with time to death or respiratory hospitalisation in the ISABELA studies were integrated into a single composite score. This score was then validated in an external cohort.

resultsThere were 1251 patients in the derivation set with 83 respiratory-related hospitalisations and 21 deaths observed after 48 weeks. After multivariable analysis, four parameters were independently predictive of outcomes: Borg dyspnoea score, oxygen flow rate, oxygen saturation nadir and the 6-min walk distance. A pragmatic model, termed the ODDS (oxygen, distance, dyspnoea, saturation) was then developed. This performed better than the individual parameters alone with an area under the curve (AUC) of 0.797, 0.781 and 0.766 for events at 12, 24 and 48 weeks, respectively. The ODDS model was similarly accurate when applied to the external validation set (n=295) at 48 weeks (AUC 0.758, 95% CI 0.688-0.825).

conclusionThe 6MWT imparts important prognostic information which is best captured by combining constituent variables in a composite score system. The ODDS model might find utility in the clinical setting as well as in IPF studies where it can be used to risk-stratify patients for outcomes.

Indexed as

Idiopathic Pulmonary FibrosisWalk TestAgedArea Under CurveDyspneaExercise TestFemaleHospitalizationHumansMaleMiddle AgedMultivariate AnalysisOxygen SaturationPredictive Value of TestsPrognosisRandomized Controlled Trials as Topic

Identifiers

PMID40610052
PMCPMC12591136

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.